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Summary
Background and purpose: In Japan, there are two sleep-disordered breathing (SDB)-related
problems, which include diagnosing SDB using a portable device (PD) and treating mild-to-
moderate SDB (mm-SDB) using continuous positive airway pressure (CPAP) for severe SDB (s-SDB)
in obstructive sleep apnea (OSA) patients. Our aims were to evaluate the effectiveness of a PD
in diagnosing SDB in patients with cardiovascular disease (CVD), and to assess the difference
between mm-SDB [apnea-hypopnea index (AHI): 20—40 h−1] and s-SDB (AHI: >40 h−1) using brain
natriuretic peptide (BNP) in OSA patients.
Methods and subjects: After their underlying CVD was treated, full-night sleep studies using
polysomnography (PSG) and PD were performed on the same day.
Results: Eighty-three patients underwent full-night PSG simultaneously with PD. The average
duration of the sleep study was 8.6± 6.2 days. There was a tendency for a higher AHI value
obtained with PSG (PSG, 28.9± 24.3 h−1; PD, 22.3± 16.7 h−1; p = 0.05). However, the speciﬁcity
and sensitivity of diagnosing SDB using PD were 86% and 81%, respectively. Using PD, twenty-
nine OSA patients had mm-SDB and eleven patients had s-SDB. The BNP value was higher in the
mm-SDB patients (318± 550 pg/ml) than in the s-SDB patients (202± 160 pg/ml).
Conclusions: The PD was effective in diagnosing SDB in patients with CVD. The BNP value was
higher in the mm-SDB patients. Therefore, they need to be treated with CPAP to treat underlying
CVD.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ntroduction
leep-disordered breathing (SDB) is closely related to car-
iovascular disease (CVD), including heart failure (HF)
nd coronary artery disease (CAD) [1—4]. Furthermore,
e reported that SDB is a strong risk factor for fatal
ardiovascular events including acute myocardial infarc-
ion, fatal arrhythmias, and cardio-embolic stroke [5]. In
uture, it might be more important to diagnose and treat
DB in order to treat underlying CVD. However, there
emain two problems related to SDB. These include diag-
osing SDB using a portable device (PD), and treating
ild-to-moderate SDB (mm-SDB) [apnea-hypopnea index
AHI): 20—40 h−1] using continuous positive airway pressure
CPAP) for patients with obstructive sleep apnea (OSA) by
apanese health insurance rules. Full-night polysomnogra-
hy (PSG) is a standard device used globally to diagnose
he type and severity of SBD. Conversely, a PD is com-
only used as a substitute to diagnose SDB. However,
his device has several problems; i.e. it is impossible to
ssess patients’ sleep and arousal periods, sleep stage,
nd electroencephalograms (EEG). Furthermore, there have
ot been many clinical trials evaluating the effective-
ess of a PD in diagnosing SDB [6—13]. Our aims were to
valuate the effectiveness of a PD in diagnosing SDB in
atients with CVD and to assess the difference between
m-SDB (AHI: 20—40 h−1) and severe-SDB (s-SDB) (AHI:
40 h−1) using brain natriuretic peptide (BNP) in patients
ith OSA.
ethods and materials
tudy population
etween December 2007 and August 2008, 99 consecutive
atients with CAD who were admitted to hospital because
f anterior chest pain, or with HF who had symptoms deﬁned
s the establishment of New York Heart Association grade II
r IV participated in the study. This study was conducted
n accordance with the recommendations of the Helsinki
eclaration of 1975, and the protocol was approved by our
edical Center Institutional Review Board. Informed con-
ent was provided by each patient before entering into the
tudy. In the course of our study, no adverse effects were
bserved and there was no change to the protocol after the
tudy began. Sixteen patients without sufﬁcient sleep study
ata were excluded.
ata collection
aseline data included transthoracic echocardiography,
edical history, physical examination, and biochemi-
al examination of blood. After treating the underlying
isease, transthoracic echocardiography was performed
efore the overnight sleep study. Venous blood sam-
les were obtained on admission, after an overnight
ast. BNP levels were estimated before the study. Arte-
ial blood samples were obtained for blood gas analysis
hen the patients were supine and not receiving supple-
ental oxygen. Dyslipidemia was deﬁned as the current
a
s
S
u
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se of cholesterol-lowering drugs, a triglyceride value of
150mg/dl, a low-density lipoprotein cholesterol value of
140mg/dl, and/or a high-density lipoprotein cholesterol
alue of <40mg/dl. Hypertension was deﬁned as the cur-
ent use of antihypertensive drugs or a blood pressure
f ≥140/90mmHg. Diabetes mellitus was deﬁned as the
urrent use of insulin or antidiabetic drugs, fasting blood
lucose value of ≥126mg/dl, and/or a hemoglobin A1c value
f ≥6.5%.
leep study
ll procedures were performed at our medical center.
atients receiving inotropic therapy were studied after this
reatment was discontinued. After their underlying CVD was
reated, full-night sleep studies using PSG and PD were
erformed on the same day. The average duration of the
leep study was 8.6± 6.2 days. During sleep evaluation,
ll patients underwent overnight PSG using a digital poly-
raph (P-Series Plus; Compumedics, Abbotsville, Australia).
he assessment included EEG monitoring, an electroocu-
ogram, a chin electromyogram, and monitoring of chest
nd abdominal movements using two bands (inductive res-
iratory bands). Airﬂow was assessed using a thermistor.
rterial oxygen saturation (SaO2) was measured continu-
usly using a pulse oximeter with a ﬁnger probe (Nonin
000J Adult Flex Sensor, Plymouth, MN, USA) (sampling
requency: 1 s). Sleep staging and arousals were scored
ccording to standard methods [14,15]. Apnea was deﬁned
s the complete cessation of airﬂow lasting ≥10 s. Hypop-
ea was deﬁned as a ≥50% decrease in airﬂow for ≥10 s,
ccompanied by desaturation (3% decrease in SaO2) and/or
n EEG arousal response. AHI was deﬁned as the total num-
er of apneas and hypopneas per hour of sleep. An AHI of
20 h−1 was considered abnormal. The PD (Morpheus; Com-
umedics, Melbourne, Australia) was used to identify sleep
pnea and sleep time, with proper monitoring by a physi-
ian. Airﬂow (using a thermistor), SaO2, heart rate, and
espiratory movements (using chest and abdominal bands)
ere continuously monitored. The AHI was calculated as
he number of times per hour that pulse oximetry indicated
n oxygen saturation decrease of more than 4% from the
aseline oxygen saturation. Central and obstructive apnea
ere divided into forms of both airﬂow and movement of
he chest and abdomen. To classify patients with OSA into
wo groups, the AHI score using PD was selected in this
tudy.
tatistical analysis
esults are expressed as means± standard deviations, or
ounts (expressed as percentage). Results of the sleep study
ere compared using paired Student’s t test and clinical
haracteristics of the OSA population were compared using
npaired Student’s t test for continuous variables and a
hi-square test for categorical variables. A receiver oper-
ting characteristic (ROC) curve was drawn to show the
ensitivity and speciﬁcity of each observed value of AHI.
igniﬁcance was set at 5% and all analyses were performed
sing JMP software (JMP 6.0; SAS Institute Inc., Cary, NC,
SA).
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Table 1 Characteristics of the study population.
Total (n = 83)
Age, years 70± 10
Males, n (%) 48 (58)
Coronary risk factors, n (%)
Hypertension 75 (90)
Dyslipidemia 60 (72)
Diabetes mellitus 45 (54)
Current smoking 16 (19)
Underlying cardiovascular diseases, n (%)
Coronary artery disease 38 (46)
Valvular disease 16 (19)
Cardiomyopathy 16 (19)
Others 13 (16)
Left ventricular ejection fraction (%) 54± 15
Left ventricular wall thickness (mm) 10.6± 2.2
Left atrial diameter (mm) 40.3± 9.6
Blood pressure (mmHg)
Systolic 132± 21
Diastolic 74± 12
Triglyceride (mg/dl) 130± 83
High-density lipoprotein cholesterol (mg/dl) 48± 19
Low-density lipoprotein cholesterol (mg/dl) 107± 33
Fasting glucose (mg/dl) 117± 49
Brain natriuretic peptide (pg/ml) 411± 615
HOMA-IR 2.51± 2.76
Arterial CO2 tension (mmHg) 38.6± 4.8
Arterial O2 tension (mmHg) 85.0± 18.1
Table 2 Results of sleep study.
Portable
device
Polysomnography p-Value
Total sleep
time (min)
259 ± 150
Total recording
time (min)
493 ± 178
Sleep
efﬁciency (%)
38.6 ± 21.2
Apnea
hypopnea
index (h)
22.3 ± 16.7 28.9 ± 24.3 0.05
Apnea index (h) 8.0 ± 14.3 12.4 ± 17.1 <0.001
Baseline
oxygen
saturation
level (%)
96.1 ± 1.4 96.5 ± 2.1 N.S.
Lowest oxygen
saturation
level (%)
84.7 ± 7.1 84.3 ± 7.1 N.S.
Arousal index
(h)
10.3 ± 17.4
Cumulative
percentage
time at a
pulse-
oximetric
oxygen
saturation
below 90%
(%)
2.8 ± 7.2 4.8 ± 10.2 0.10
Data are presented as means± standard deviations. N.S., not
signiﬁcant.Data are presented as means± standard deviations or num-
ber of subjects (percentage). HOMA-IR, homeostasis model
assessment-insulin resistance.
Results
The study group consisted of 83 CVD patients. Patient char-
acteristics are shown in Table 1. The data from sleep study
using PSG and the PD are summarized in Table 2. The PD
indicated that 40 of 83 patients (48%) had OSA, including
29 with mm-SDB and 11 with s-SDB. There was a ten-
dency for a higher AHI value obtained with PSG compared
with the AHI value obtained with PD (PSG, 28.9± 24.3 h−1;
PD, 22.3± 16.7 h−1; p = 0.05). An ROC curve (cut-off point:
>20 h−1) was drawn to show the sensitivity and speciﬁcity
of each observed value of AHI (Fig. 1). The speciﬁcity and
sensitivity of diagnosing SDB using PD were 86% and 81%,
respectively. To assess the relationships between the sever-
ity of SDB and CVD using BNP value in OSA patients, we
classiﬁed patients with OSA into two groups; i.e. those
with mm-SDB (AHI 20—40 h−1) and those with s-SDB (AHI
>40 h−1). In the two groups, sleep disordered symptoms were
checked by Epworth Sleepiness Scale. There was no sig-
niﬁcant difference between the two groups with respect
to Epworth Sleepiness Scale (mm-SDB, 7.7± 3.5; s-SDB,
9.5± 4.1; p = 0.19). The age of the patients was signiﬁcantly
different between the two groups (mm-SDB, 69± 8 years;
s-SDB, 62± 11 years; p = 0.03); however, there was no sig-
niﬁcant difference between the two groups with respect
to gender, drug therapy, or transthoracic echocardiography
Figure 1 Receiver operating characteristic (ROC) curve for
the portable device. ROC referred to an apnea hypopnea index
of ≥20 h−1 with polysomnography. The area under the curve is
0.87 (p < 0.0001), which indicates a high sensitivity and speci-
ﬁcity in diagnosing sleep-disordered breathing.
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Table 3 Clinical characteristics of the obstructive sleep apnea population.
mm-SDB s-SDB p-Value
(n = 29) (n = 11)
Age, years 69± 8 62± 11 0.03
Male, n (%) 19 (66) 6 (55) N.S.
Body mass index (kg/m2) 25.1± 3.8 28.9± 8.5 0.06
Diabetes mellitus, n (%) 20 (69) 7 (64) N.S.
Hypertension, n (%) 28 (97) 10 (91) N.S.
Dyslipidemia, n (%) 22 (76) 9 (82) N.S.
Current smoker, n (%) 8 (16) 17 (18) N.S.
Underlying cardiovascular diseases, n (%)
Coronary artery disease 16 (55) 3 (27) N.S.
Valvular disease 7 (24) 2 (18) N.S.
Cardiomyopathy 1 (4) 4 (37) 0.004
Others 5 (17) 2 (18) N.S.
Left ventricular ejection fraction (%) 59± 12 57± 15 N.S.
Left ventricular wall thickness, mm 11.4± 3.1 10.2± 1.6 N.S.
Left atrial diameter, mm 42.0± 10.8 40.8± 9.4 N.S.
Blood pressure (mmHg)
Systolic 130± 24 128± 22 N.S.
Diastolic 75± 14 75± 10 N.S.
Fasting blood sugar (mg/dl) 116± 34 150± 94 0.09
Low-density lipoprotein cholesterol (mg/dl) 106± 37 108± 34 N.S.
High-density lipoprotein cholesterol (mg/dl) 46± 20 53± 22 N.S.
Triglyceride (mg/dl) 146± 90 136± 99 N.S.
Brain natriuretic peptide (pg/ml) 318± 550 202± 160 N.S.
HOMA-IR 3.75± 3.90 2.32± 1.45 N.S.
Arterial O2 tension (mmHg) 86.5± 19.0 74.4± 9.2 0.05
Arterial CO2 tension (mmHg) 38.1± 4.5 40.8± 3.7 0.08
RRI variability indices
LF/HF-ratio 1.52± 1.29 1.84± 1.69 N.S.
SDNN (ms) 128.3± 169.1 111.4± 50.9 N.S.
pNN50 (%) 19.5± 31.1 24.6± 29.9 N.S.
Data are presented as means± standard deviations or number of subjects (percentage). mm-SDB, mild-to-moderate obstructive sleep-
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RRI, RR interval; LF, low frequency; HF, high frequency; SDNN, st
with a difference greater than 50ms; N.S., not signiﬁcant.
arameters including left ventricular ejection fraction, left
entricular wall thickness, and left atrial diameter. In terms
f coronary risk factors, there was no signiﬁcant differ-
nce in the frequency of dyslipidemia, hypertension, and
iabetes mellitus. The results of the blood gas analysis indi-
ated that arterial O2 tension tended to be greater in the
m-SDB patients. The BNP value was higher in the mm-
DB patients (318± 550 pg/ml) than in the s-SDB patients
202± 160 pg/ml); however, this difference was not signiﬁ-
ant (Table 3).
iscussion
n the present study, we examined sleep study data of
atients with CVD in order to determine whether a PD can
e substituted for PSG, and whether mild-to-moderate OSA
s related to a high BNP level, which may indicate cardiac
train including diastolic dysfunction. Our results indicate
hat the PD was effective in diagnosing SDB in patients with
t
w
P
s
thing; HOMA-IR, homeostasis model assessment-insulin resistance;
d deviation of all RRIs; pNN50, the proportion of successive RRIs
VD, and patients with mild-to-moderate OSA suffer from
evere cardiac strain, thus indicating that these patients
hould be treated using CPAP and other treatment devices.
ntil recently, PSG has been the standard method used glob-
lly to diagnose SDB [14—16]. However, the results of several
tudies suggest that the PD is effective and useful in diagnos-
ng SDB, and can reduce the need for diagnostic PSG [6—13].
e calculated the AHI value using PSG and the PD in order
o evaluate the effectiveness of the PD in patients with
VD. From the view of impossibility of assessing patients’
leep and arousal periods, and difference of checking oxy-
en saturation decrease (3% or 4%), the AHI value with PD
as expected to be lower. Table 2 shows the AHI values
btained in 83 patients in this study. The AHI values with the
methods were not signiﬁcantly different, but there was aendency for a higher AHI value obtained with PSG compared
ith the AHI value obtained with PD (PSG, 28.9± 24.3 h−1;
D, 22.3± 16.7 h−1; p = 0.05). Evidence that the PD is sub-
tantially comparable in function and capabilities to PSG is
hat the diagnostic speciﬁcity and sensitivity (86% and 81%,
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respectively) for patients with SDB were sufﬁciently high
(Fig. 1). Our study found that the PD was as effective as PSG
in diagnosing SDB.
Past literature has shown that several devices are
effective for patients with HF [17,18]. Furthermore, CPAP
treatment can improve left ventricular ejection fraction in
patients with moderate-to-severe OSA (mean AHI: ≥20 h−1)
using PSG [19], and that untreated OSA is associated with
an increased risk of death and fatal cardiovascular events
[5,20]. Furthermore, CPAP treatment can reduce the risk
of CVD in patients with mild OSA (mean AHI: 15 h−1) [21].
Alternatively, a high BNP level is a signiﬁcant predictor of
cardiovascular events, including mortality, hospitalization,
and redecompensation in patients with HF [22—25]. There-
fore, we examined sleep study data of CVD patients with OSA
in order to determine the need for treatment of mm-SDB
using BNP values. We found that the BNP values in mm-
SDB and s-SDB patients were equivalently high (mm-SDB,
318± 550 pg/ml; s-SDB, 202± 166 pg/ml; Table 3), and even
patients who had low AHI had already suffered from severe
cardiac strain (BNP 533± 704 pg/ml). For treatment of CVD
(not sleep apnea treatment), it is very important to treat
these patients using CPAP.
However, there are some limitations. The PD does not
allow electroencephalographic responses to be recorded,
and is unable to assess sleep stages. In this study, total
sleep time using PSG and total recording time using PD
were different. Furthermore, the AHI values with the 2
methods were not signiﬁcantly different, but there was a
tendency for a higher AHI value obtained with PSG com-
pared with the AHI value obtained with PD. Hence, PSG
is still the standard device used globally to diagnose SDB.
Considering the fact that many patients with CVD suffer
from SDB [26,27], it is difﬁcult to diagnose SDB using PSG
in all the patients. Therefore, we believe that the use
of PD is effective in the diagnosis of SDB. In this study,
body mass index (BMI) was higher in the s-SDB patients
than in the mm-SDB patients (Table 3). BNP levels are
relatively lower in overweight (BMI 25.0—29.9 kg/m2) and
obese (BMI≥ 30.0 kg/m2) HF patients, and lower BNP cut-
points are needed for diagnosing HF in overweight and obese
patients [28,29]; however, BNP levels were sufﬁciently-high
in the mm-SDB patients (318± 550 pg/ml). They have suf-
fered from CVD including HF, and need to be treated with
CPAP to treat underlying CVD. In conclusion, our study found
that PD is as effective as PSG in diagnosing SDB in patients
with CVD, and that BNP values in patients with mm-SDB and
s-SDB were equivalently high, and patients with mm-SDB
need to be treated with CPAP in order to treat underlying
CVD.
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